These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17965366)

  • 1. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
    Santos KVD; Nicoli JR; Martins WA; Coutinho SC; Apolônio ACM; Diniz CG; Carvalho MAR; Farias LM
    J Med Microbiol; 2007 Nov; 56(Pt 11):1576-1579. PubMed ID: 17965366
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
    Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
    J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
    Dela Pena AS; Asperger W; Köckerling F; Raz R; Kafka R; Warren B; Shivaprakash M; Vrijens F; Giezek H; DiNubile MJ; Chan CY;
    J Gastrointest Surg; 2006 Apr; 10(4):567-74. PubMed ID: 16627223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic profiling of commonly prescribed antimicrobial drugs against Escherichia coli isolates from urinary tract.
    Cuba GT; Pignatari AC; Patekoski KS; Luchesi LJ; Kiffer CR
    Braz J Infect Dis; 2014; 18(5):512-7. PubMed ID: 24731938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
    Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
    Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
    Valéria Dos Santos K; Roque DE Carvalho MA; Amancio Martins W; Coutinho SC; Bahia JL; Lopes DE Andrade JP; Morais Apolonio AC; Cara DC; Galuppo Diniz C; Nicoli JR; DE Macedo Farias L
    J Chemother; 2010 Aug; 22(4):259-63. PubMed ID: 20685630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
    Goldstein EJ; Citron DM; Tyrrell KL; Leoncio ES; Merriam CV
    Anaerobe; 2017 Feb; 43():1-3. PubMed ID: 27713022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
    Barboza E; Solomkin J; Goldstein EJ; del Castillo M; Alvarado R; Barboza A; Teppler H
    Rev Gastroenterol Peru; 2003; 23(3):192-8. PubMed ID: 14532920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
    Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
    Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
    Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
    Jansen JP; Kumar R; Carmeli Y
    Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance in the Bacteroides fragilis group in faecal microbiota from healthy Danish children.
    Sydenham TV; Jensen BH; Petersen AM; Krogfelt KA; Justesen US
    Int J Antimicrob Agents; 2017 May; 49(5):573-578. PubMed ID: 28366659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis.
    Huelves L; Gracia M; Del Prado G; Rodríguez-Cerrato V; Martínez-Marín C; Ponte C; Soriano F; Coronel P; Gimeno M; Blanco J
    Int J Antimicrob Agents; 2006 Aug; 28(2):151-3. PubMed ID: 16815688
    [No Abstract]   [Full Text] [Related]  

  • 20. Case-control study of drug monitoring of β-lactams in obese critically ill patients.
    Hites M; Taccone FS; Wolff F; Cotton F; Beumier M; De Backer D; Roisin S; Lorent S; Surin R; Seyler L; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2013 Feb; 57(2):708-15. PubMed ID: 23147743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.